Vaxcyte (PCVX) Capital Expenditures (2019 - 2026)

Vaxcyte (PCVX) has reported Capital Expenditures for 8 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 61.15% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $4.2 million (down 80.96% YoY), while the FY2025 annual figure was $7.5 million, down 66.39% from the prior year.
• Capital Expenditures advanced to $2.1 million in Q1 2026 per PCVX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $15.6 million in Q4 2023 and bottomed at -$4.6 million in Q4 2022.
• Historically, Capital Expenditures has averaged $2.8 million across 5 years, with a median of $2.0 million in 2025.
• On a YoY basis, Capital Expenditures climbed as much as 744.73% in 2023 and fell as far as 542.35% in 2023.
• Vaxcyte's Capital Expenditures stood at -$4.6 million in 2022, then soared by 440.43% to $15.6 million in 2023, then slumped by 74.27% to $4.0 million in 2024, then slumped by 51.01% to $2.0 million in 2025, then gained by 6.95% to $2.1 million in 2026.
• Business Quant data shows PCVX's Capital Expenditures at $2.1 million in Q1 2026, $2.0 million in Q4 2025, and -$1.7 million in Q3 2025.